Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4405 ARTÍCULOS , VIENDO DEL 601 AL 615

Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment

Senek M, Aquilonius SM, Askmark H, Bergquist F, Constantinescu R, Ericsson A, Lycke S, Medvedev A, Memedi M, Ohlsson F, Spira J, Westin J, Nyholm D.

Eur J Clin Pharmacol. 2017 May;73(5):563-571. doi: 10.1007/s00228-017-2196-4. Epub 2017 Jan 18.

Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease

Brockmann K, Schulte C, Schneiderhan-Marra N, Apel A, Pont-Sunyer C, Vilas D, Ruiz-Martinez J, Langkamp M, Corvol JC, Cormier F, Knorpp T, Joos TO, Bernard A, Gasser T, Marras C, Schüle B, Aasly JO, Foroud T, Marti-Masso JF, Brice A, Tolosa E, Berg D, Maetzler W.

Eur J Neurol. 2017 Feb;24(2):427-e6. doi: 10.1111/ene.13223.

Integrating Patient Concerns into Parkinson's Disease Management

Lim SY, Tan AH, Fox SH, Evans AH, Low SC.

Curr Neurol Neurosci Rep. 2017 Jan;17(1):3. doi: 10.1007/s11910-017-0717-2.

Managing Ethical Dilemmas in End-Stage Neurodegenerative Diseases

Low JA, Ho E.

Geriatrics (Basel). 2017 Jan 20;2(1):8. doi: 10.3390/geriatrics2010008.

Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology

O'Brien JT, Holmes C, Jones M, Jones R, Livingston G, McKeith I, Mittler P, Passmore P, Ritchie C, Robinson L, Sampson EL, Taylor JP, Thomas A, Burns A.

J Psychopharmacol. 2017 Feb;31(2):147-168. doi: 10.1177/0269881116680924. Epub 2017 Jan 20.

Dopamine agonist withdrawal syndrome: A comprehensive review

Yu XX, Fernandez HH.

J Neurol Sci. 2017 Mar 15;374:53-55. doi: 10.1016/j.jns.2016.12.070. Epub 2017 Jan 2.

Selective neuronal vulnerability in Parkinson disease

Surmeier DJ, Obeso JA, Halliday GM.

Nat Rev Neurosci. 2017 Jan 20;18(2):101-113. doi: 10.1038/nrn.2016.178.

Opioid system in L-DOPA-induced dyskinesia

Pan J, Cai H.

Transl Neurodegener. 2017 Jan 17;6:1. doi: 10.1186/s40035-017-0071-y. eCollection 2017.

Aneurysm of the muscular septum associated with Wolf-Parkinson-White syndrome presenting as dilated cardiomyopathy; A report of two cases

Doğan V, Ertuğrul İ, Kayalı Ş, Örün UA, Karademir S.

Turk Kardiyol Dern Ars. 2017 Jan;45(1):85-88. doi: 10.5543/tkda.2016.44038.

Precision medicine for disease modification in Parkinson disease

Espay AJ, Brundin P, Lang AE.

Nat Rev Neurol. 2017 Feb;13(2):119-126. doi: 10.1038/nrneurol.2016.196. Epub 2017 Jan 20.

The psychosis spectrum in Parkinson disease

Ffytche DH, Creese B, Politis M, Chaudhuri KR, Weintraub D, Ballard C, Aarsland D.

Nat Rev Neurol. 2017 Feb;13(2):81-95. doi: 10.1038/nrneurol.2016.200. Epub 2017 Jan 20.

Physical Therapy Versus a General Exercise Programme in Patients with Hoehn Yahr Stage II Parkinson's Disease: A Randomized Controlled Trial

Dipasquale S, Meroni R, Sasanelli F, Messineo I, Piscitelli D, Perin C, Cornaggia CM, Cerri CG.

J Parkinsons Dis. 2017;7(1):203-210. doi: 10.3233/JPD-161015.

Hallucinations and the spectrum of psychosis in Parkinson's disease

Frei K, Truong DD.

J Neurol Sci. 2017 Mar 15;374:56-62. doi: 10.1016/j.jns.2017.01.014. Epub 2017 Jan 5.

Palliative care and Parkinson's disease: Meeting summary and recommendations for clinical research

Kluger BM, Fox S, Timmons S, Katz M, Galifianakis NB, Subramanian I, Carter JH, Johnson MJ, Richfield EW, Bekelman D, Kutner JS, Miyasaki J.

Parkinsonism Relat Disord. 2017 Apr;37:19-26. doi: 10.1016/j.parkreldis.2017.01.008. Epub 2017 Jan 11.

Traditional Chinese medicine for modern treatment of Parkinson's disease

Han L, Xie YH, Wu R, Chen C, Zhang Y, Wang XP.

Chin J Integr Med. 2017 Aug;23(8):635-640. doi: 10.1007/s11655-016-2537-7. Epub 2017 Jan 20.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias